Magenta Therapeutics Inc (NASDAQ:MGTA) insider Jason Gardner sold 14,000 shares of the company’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $15.11, for a total value of $211,540.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
NASDAQ:MGTA opened at $14.26 on Thursday. The stock has a 50 day moving average price of $15.36. Magenta Therapeutics Inc has a 52 week low of $5.31 and a 52 week high of $21.00. The firm has a market capitalization of $504.46 million and a P/E ratio of -4.56.
Magenta Therapeutics (NASDAQ:MGTA) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.11. On average, analysts expect that Magenta Therapeutics Inc will post -2.03 EPS for the current year.
A number of equities analysts have recently weighed in on MGTA shares. Raymond James started coverage on Magenta Therapeutics in a report on Thursday, March 14th. They issued an “outperform” rating on the stock. Goldman Sachs Group downgraded Magenta Therapeutics from a “buy” rating to a “neutral” rating and dropped their target price for the company from $17.00 to $16.00 in a report on Sunday, March 24th. They noted that the move was a valuation call. Zacks Investment Research upgraded Magenta Therapeutics from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a report on Saturday, March 23rd. Finally, Wedbush restated an “outperform” rating and issued a $22.00 price objective on shares of Magenta Therapeutics in a report on Friday, May 10th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $19.00.
Magenta Therapeutics Company Profile
Magenta Therapeutics, Inc, a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases.
Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.